Associate Commissioner for Minority Health and Director of the Office of Minority Health and Health Equity (OMHHE) at the FDA RADM Richardae Araojo shared her thoughts on the importance of promoting diverse populations to be included in clinical trials. The OMHHE has developed a Diversity in Clinical Trials Initiative in response to underrepresentation in clinical trials by historically marginalized populations.
Araojo remarks, “Another key component to the Initiative is stakeholder engagement. We realize that we cannot do this work in a silo and actively find opportunities to engage with stakeholders—including federal partners, industry, non-profit organizations, academia, community organizations, consumer groups, medical providers, among others to encourage diversity and inclusion in clinical trials.” Read more here.
(Source: RADM Richardae Araojo, Pharm.D., MS, PhRMA, 5/12/21)